We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -1.27% | 39.00 | 38.50 | 39.50 | 39.50 | 38.50 | 39.50 | 335,898 | 15:55:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Misc Retail Stores, Nec | 43.98M | 520k | 0.0041 | 95.12 | 49.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/5/2018 13:10 | Lauders £400k 10 year convertible loan note @6.5% coupon. Shareholders hung out to dry. The boffins can continue to have a jolly good time :-( Cynical from Coventry. red | redartbmud | |
02/5/2018 10:33 | Brings me out in tiny, tiny spots, Lauders! apad😊 | apad | |
02/5/2018 10:29 | Apad - The FARN BB has seen a marked increase in activity recently. Still not "that popular" yet ;-) BVXP has been doing well recently. HCM too. red - NANO news again. Apad had better not look. Grants, nano and graphene all mentioned in one RNS! | lauders | |
02/5/2018 10:11 | Schroders backing Warpaint. IQE LTIP! Finished with FARN now. It's 3.2% of Stairway. Only a few things to add to dacian's comment. There are no competitors. They will be producers. The drug mechanism is not limited to lungs. Although not that widely researched, I have not seen such convincing Phase II results. Phase III trials seem to be conducted on borderline Phase II results. apad😎 | apad | |
02/5/2018 08:43 | Hope so, homebrewruss, bought more this morning at 794.75. Just following my big fierce animals principle. Can't say I understand why the price is falling below the placing on the run up to results though. Sorry, red, insensitive of me. apad | apad | |
01/5/2018 22:43 | APAD, this is partly why I was asking what your price expectations were for FARN a few days ago. It has already had a great run over the past year or so. If you have a look at MTFB last year for example, it rose strongly after the trial completion and until the positive results were announced and has since fallen back and not done too much. Hopefully you will prove us all wrong with your strategy however :) | homebrewruss | |
01/5/2018 22:30 | I think FARN at current sp, has some degree of success built into the sp, so how much gain or loss you get based on good or bad results is impossible to predict. You should only allocate the money you can afford to lose to early stage pharma. When I bought more TUNE before the results, I was more sure that share price will rise after results than fall, but can I say the same about FARN, no | modform | |
01/5/2018 22:29 | FARN .....The other issue is the outcome isn't down to the skill of the company - its down to what the compound does; and how the regulator interprets the data If it is safe and it does give benefit then fine; but however good the company the decision is based on the compounds performance. Risky in my book; especially for a large stake. I wish you well with it. | janeann | |
01/5/2018 21:42 | It's a binary event - like 'investing' in a company drilling an oil well. Very different from investing in a quality sustainable business growing organically where value is not contingent on one single event. Re HP example I'm not keen on companies that make large (or in fact any) acquisitions as I've said here before. They add large risks where these didn't exist before the purchase. CLLN was just a poor quality business so not really relevant to this situation. You may well think you understand FARN and the odds are stacked in your favour. In fact I wouldn't bet against you. It's just not for me. | hydrus | |
01/5/2018 21:24 | Hydrus, HP spent 7billion on Autonomy that they wrote off one year later. Was that gambling? Or was it an incorrect judgement? I don't see my analysis of FARN as a 'gamble'. Clearly a bad Phase III result is sudden death. However, CLLN was just a slow death. In some ways all investing is on a spectrum of risk. Ney Ho. apad | apad | |
01/5/2018 19:16 | Thanks epo. Sorted. | thelongandtheshortandthetall | |
01/5/2018 18:53 | thelongandtheshortan | epo001 | |
01/5/2018 18:49 | Just stumbled onto really healpful site www.dividenddata.co. Worth a look gang. | thelongandtheshortandthetall | |
01/5/2018 17:43 | Fun preentation: www.piworld.co.uk/20 | apad | |
01/5/2018 17:23 | APAD you might feel the odds are good but it is gamble. They sort of have to get on and invest in manufacturing right? Don't think that's conclusive of anything. Any way good luck to those in it. | hydrus | |
01/5/2018 17:22 | Dice are loaded, Hydrus. apad😊 | apad | |
01/5/2018 17:19 | They have two manufacturing facilities and this was 29th Jan 2018, budsman. "Faron’s wholly-owned product for Acute Respiratory Distress Syndrome on track for Phase III data in H1 2018 Faron Pharmaceuticals Ltd (“Faron” Fast Track designation is granted by the FDA to expedite the review and facilitate the development of drugs to treat serious conditions with significant unmet medical need. The purpose of the process is to get new drugs to patients quicker. Today’s announced Fast Track designation is in addition to Traumakine’s Promising Innovative Medicines (PIM) designation from the MHRA, which is the first stage of the MHRA’s Early Access Medicines Scheme (EAMS). | apad | |
01/5/2018 17:18 | Well, presumably those in FARN acknowledge it's just a straight gamble rather than a serious investment? Not my kind of thing. If I want to gamble I'll put a tenner on the horses rather than risk serious money. | hydrus | |
01/5/2018 17:04 | Hopefully not bad news leaking out at FARN. Bud | budsman | |
01/5/2018 17:04 | Duplicate - apologies Bud | budsman | |
01/5/2018 17:00 | No longer showing this BOO short. "JPMorgan Asset Management (UK) Short 0.50% 0.50% 16 Apr 2018" From IGG: "It’s a double whammy as they also scaled down their long position. It was the JPM UK Equity Growth fund that looks like the guys that de-risked. BOO was their biggest recent decrease in position selling 77k shares @ 153p (ish) = 1.1m value of stock. Market cap of BOO (at time of sale) = 1,757m Sold mkt cap equiv = 0.06%" My timing on FARN purchases is rubbish. apad😡 | apad |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions